Results 21 to 30 of about 60,658 (250)

How glucagon-like peptide 1 receptor agonists work

Endocrine Connections, 2021
In recent years, glucagon-like peptide 1 receptor agonists (GLP-1RAs) have become central in the treatment of type 2 diabetes (T2D). In addition to their glucose-lowering properties with low risk of hypoglycaemia, GLP-1RAs reduce body weight and show ...
Christine Rode Andreasen, Andreas Andersen, Filip Krag Knop, Tina Vilsbøll   +3 more
doaj   +1 more source

Systemic GLP-1R agonist treatment reverses mouse glial and neurovascular cell transcriptomic aging signatures in a genome-wide manner

Communications Biology, 2021
Li, Chen, Vong, Zhao et al. show that glucagon-like peptide-1 receptor agonist reverses transcriptomic aging signatures in mouse glial and neurovascular cells.
Zhongqi Li, Xinyi Chen, Joaquim S. L. Vong, Lei Zhao, Junzhe Huang, Leo Y. C. Yan, Bonaventure Ip, Yun Kwok Wing, Hei-Ming Lai, Vincent C. T. Mok, Ho Ko   +10 more
doaj   +1 more source

Selective polypeptide ligand binding to the extracellular surface of the transmembrane domains of the class B GPCRs GLP-1R and GCGR

iScience, 2023
Summary: Crystal and cryo-EM structures of the glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) bound with their peptide ligands have been obtained with full-length constructs, indicating that the extracellular domain (ECD) is ...
Huixia Wang, Wanhui Hu, Tiandan Xu, Ya Yuan, Dongsheng Liu, Kurt Wüthrich   +5 more
doaj   +1 more source

The therapeutic potential of glucagon-like peptide-1 receptor analogs for neuroinflammation in the setting of asthma [PDF]

Exploration of Asthma & Allergy
Glucagon-like peptide-1 (GLP-1) is a hormone that regulates blood glucose levels and is produced by the enteroendocrine glands in the large and small intestines in response to the consumption of foods that contain carbohydrates, fats, and proteins.
Courtney Lehman, Ray Stokes Peebles Jr
doaj   +1 more source

Super-resolution microscopy compatible fluorescent probes reveal endogenous glucagon-like peptide-1 receptor distribution and dynamics

Nature Communications, 2020
Glucagon-like peptide-1 receptor is an important regulator of appetite and glucose homeostasis. Here the authors describe super-resolution microscopy and in vivo imaging compatible fluorescent probes, which reveal endogenous glucagon-like peptide-1 ...
Julia Ast, Anastasia Arvaniti, Nicholas H. F. Fine, Daniela Nasteska, Fiona B. Ashford, Zania Stamataki, Zsombor Koszegi, Andrea Bacon, Ben J. Jones, Maria A. Lucey, Shugo Sasaki, Daniel I. Brierley, Benoit Hastoy, Alejandra Tomas, Giuseppe D’Agostino, Frank Reimann, Francis C. Lynn, Christopher A. Reissaus, Amelia K. Linnemann, Elisa D’Este, Davide Calebiro, Stefan Trapp, Kai Johnsson, Tom Podewin, Johannes Broichhagen, David J. Hodson   +25 more
doaj   +1 more source

Crystal Structure of Glucagon-like Peptide-1 in Complex with the Extracellular Domain of the Glucagon-like Peptide-1 Receptor [PDF]

Journal of Biological Chemistry, 2010
GLP-1 (glucagon-like peptide-1) is an incretin released from intestinal L-cells in response to food intake. Activation of the GLP-1 receptor potentiates the synthesis and release of insulin from pancreatic beta-cells in a glucose-dependent manner. The GLP-1 receptor belongs to class B of the G-protein-coupled receptors, a subfamily characterized by a ...
Underwood, Christina Rye, Garibay, P., Knudsen, L.B., Hastrup, S., Peters, Günther H.J.; id_orcid 0000-0001-9754-2663, Rudolph, R., Reedtz-Runge, S.   +6 more
openaire   +3 more sources

Glucagon‐like peptide‐1 receptor expression in the human eye [PDF]

Diabetes, Obesity and Metabolism, 2018
Semaglutide is a human glucagon‐like peptide‐1 (GLP‐1) analogue that is in development for the treatment of type 2 diabetes. In the pre‐approval cardiovascular outcomes trial SUSTAIN 6, semaglutide was associated with a significant increase in the risk of diabetic retinopathy (DR) complications vs placebo.
Josephine B. Hebsgaard, Charles Pyke, Emre Yildirim, Lotte B. Knudsen, Steffen Heegaard, Peter H. Kvist   +5 more
openaire   +4 more sources

Glucagon-Like Peptide-1 Receptor Imaging for Localization of Insulinomas [PDF]

The Journal of Clinical Endocrinology & Metabolism, 2009
The surgical removal of insulinomas is hampered by difficulties to localize it using conventional radiological procedures. Recently these tumors were shown to exhibit a very high density of glucagon-like peptide-1 receptors (GLP-1R) in vitro that may be used as specific targets for in vivo receptor radiolabeling.The objective of the study was to test ...
Christ, Emanuel, Wild, Damian, Forrer, Flavio, Brändle, Michael, Sahli, Rahel, Clerici, Thomas, Gloor, Beat, Martius, Ferdinand, Maecke, Helmut, Reubi, Jean Claude   +9 more
openaire   +4 more sources

Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 agonists as potential neuroprotective agents

Neural Regeneration Research, 2019
Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 receptor agonists is a breakthrough in the field of neural regeneration research increasing glucagon like peptide-1 bioavailability, hence its neuroprotective activities.
Shaker A Mousa, Bassam M Ayoub
doaj   +1 more source

Multiple Factors Related to the Secretion of Glucagon-Like Peptide-1

International Journal of Endocrinology, 2015
The glucagon-like peptide-1 is secreted by intestinal L cells in response to nutrient ingestion. It regulates the secretion and sensitivity of insulin while suppressing glucagon secretion and decreasing postprandial glucose levels.
XingChun Wang, Huan Liu, Jiaqi Chen, Yan Li, Shen Qu   +4 more
doaj   +1 more source